benserazide has been researched along with Age-Related Memory Disorders in 3 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although patients with Parkinson's disease show impairments in cognitive performance even at the early stage of the disease, the synaptic mechanisms underlying cognitive impairment in this pathology are unknown." | 1.38 | Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease. ( Calabresi, P; Costa, C; de Iure, A; Di Filippo, M; Di Luca, M; Gardoni, F; Ghiglieri, V; Latagliata, EC; Marti, M; Morari, M; Pascucci, T; Pendolino, V; Picconi, B; Puglisi-Allegra, S; Sgobio, C; Siliquini, S; Spillantini, MG; Tantucci, M; Tozzi, A, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Loiodice, S | 1 |
| Wing Young, H | 1 |
| Rion, B | 1 |
| Méot, B | 1 |
| Montagne, P | 1 |
| Denibaud, AS | 1 |
| Viel, R | 1 |
| Drieu La Rochelle, C | 1 |
| Costa, C | 1 |
| Sgobio, C | 1 |
| Siliquini, S | 1 |
| Tozzi, A | 1 |
| Tantucci, M | 1 |
| Ghiglieri, V | 1 |
| Di Filippo, M | 1 |
| Pendolino, V | 1 |
| de Iure, A | 1 |
| Marti, M | 1 |
| Morari, M | 1 |
| Spillantini, MG | 1 |
| Latagliata, EC | 1 |
| Pascucci, T | 1 |
| Puglisi-Allegra, S | 1 |
| Gardoni, F | 1 |
| Di Luca, M | 1 |
| Picconi, B | 1 |
| Calabresi, P | 1 |
| Gevaerd, MS | 1 |
| Miyoshi, E | 1 |
| Silveira, R | 1 |
| Canteras, NS | 1 |
| Takahashi, RN | 1 |
| Da Cunha, C | 1 |
3 other studies available for benserazide and Age-Related Memory Disorders
| Article | Year |
|---|---|
Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson's disease.
Topics: Amphetamine; Animals; Antiparkinson Agents; Anxiety; Benserazide; Disease Models, Animal; Dopamine; | 2019 |
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease.
Topics: alpha-Synuclein; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Biophysical Pheno | 2012 |
L-Dopa restores striatal dopamine level but fails to reverse MPTP-induced memory deficits in rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Avoidance Learning; Ben | 2001 |